Objectives: In this study we aimed to explore the pharmacokinetics of antiretroviral drugs and the immunovirological response in obese patients with HIV infection.
Introduction
Obesity has reached a high prevalence among patients living with HIV infection during the last two decades. 1, 2 Several reasons might explain this development. First, available highly active antiretroviral (ARV) treatments have led to increased virological control in about 88% of treated patients in France, 3 thereby leading to the global ageing of the HIV-infected population. 4 Second, the increasing number of patients with access to ARV and the recent American and European recommendations to treat most patients from the diagnosis of infection would impact prevalence, as ARV initiation was demonstrated to be strongly associated with weight gain and obesity. 2 Third, the increase in obesity is a worldwide multifactorial trend, due to increased calorie intake and changes in lifestyle. 5 Besides its association with cardiovascular events, obesity may affect medical care, in particular the dosing and pharmacokinetics of administered drugs. Obese people present varied body composition and regional blood circulation as compared with non-obese people, 6 affecting the body distribution of numerous therapeutic agents and therefore plasma concentrations, related in most cases to drug activity. 7, 8 Thus, obesity may be a concern for treatment with several ARV agents. In particular, NNRTIs, PIs and integrase inhibitors are lipophilic drugs and are susceptible to diffusion and entrapment in adipose tissue; their antiviral activity is related to drug plasma concentration. 9 Yet available data in this obese population are scarce. One study reported a decrease in efavirenz concentration in plasma and a large accumulation in adipocytes. 10 Therefore, assessing ARV exposure in these patients can provide critical insight into their medical care and follow-up. Obese patients living with HIV show in addition a specific response to the infection. Several studies have reported that nontreated obese or overweight patients show better immunological control than normal-weight patients, with the CD4þ T cell count remaining higher despite similar control of plasma viral load, 1, 11 and show a lower risk of developing AIDS. 12, 13 This superior immunological control was also found in obese patients receiving treatment, with faster recovery of CD4þ T cell count after ARV initiation than in normal-weight patients. 14, 15 Yet the physiological features of this protection conferred by obesity are not well understood. Adipose tissue is not a favoured site of HIV replication, with little recovery of viral RNA and integrated DNA, 10 although a recent study demonstrated potential implications for the tissue as a viral reservoir in HIV latency. 16 However, fat tissue contributes widely to an inflammatory state, with a notably large release of cytokines. 17, 18 If this continuous inflammation plays a role in immunological control, it may lead to atherosclerosis and an increase in cardiovascular events. 19 In this study, we evaluated the impact of obesity in HIVinfected patients on ARV plasma exposure and immunovirological response. Viral load and ARV drug concentrations in plasma were assayed in a cohort of HIV-infected obese patients and normal-weight patients. We assessed the impact of obesity on plasma drug concentration for ARV drugs of different classes, and the association of obesity with efficacious plasma concentrations of ARV drugs and virological failure, adjusting for covariates.
Patients and methods

Patients
The source population was HIV-1-infected patients followed from January 2009 to December 2012 in the university hospital Bichat-Claude Bernard, Paris, for whom data were collected and available in the hospital electronic database. Patients were followed according to the French recommendations, 3, 20 with viral load measurement and CD4þ T cell count frequencies between 3 and 6 months. Therapeutic drug monitoring was commonly performed 15-30 days after introduction of a new drug for various indications, such as potential drug-drug interactions, adverse events, virological failure, abnormal BMI or malabsorption suspicion. Eligible patients were >18 years old with available data on demographic characteristics, plasma viral load, CD4þ T cell count and ARV drug plasma concentration. They had received at least 1 of the 11 ARV drugs abacavir, emtricitabine, lamivudine, tenofovir disoproxil fumarate, efavirenz, nevirapine, etravirine, lopinavir, atazanavir, darunavir and raltegravir, the PIs being combined with ritonavir. We included obese patients with BMI !30 kg/m 2 according to the WHO definition, 5 who matched study eligibility criteria ( Figure 1 ). Normal-weight patients were defined as those with BMI 19-25 kg/m 2 . Each was selected to correspond in age (65 years), gender, ethnicity (African, Caucasian, Hispanic, other origins) and ARV-based regimen to one patient of the obese group. Pregnant women after the fourth month of pregnancy, hepatitis C virus-coinfected patients and those with BMI 26-30 kg/m 2 were excluded. Data on demographics (age, gender, native country), infection (date of diagnosis, viral load, CD4þ T cell count) and ART (drug, dosing regimen, treatment initiation, date of current treatment initiation, characteristics at the date of ARV drug concentration sampling) were extracted from the HIV medical database. Included patients were followed up to December 2015. Plasma HIV RNA and BMI data were available for at least 1 year after ARV drug plasma concentration determination for all included patients. Then, the date of drug switch, defined by the addition or removal of at least one drug, was recorded, as was viral load, BMI at this date, new treatment initiated, and the reason for treatment modification advocated by the physician.
Ethics
All patients enrolled in this study gave their written informed consent to having their medical chart recorded in the electronic medical record system, NADIS (Fedialis Medica, Marly Le Roi, France, French National Commission on Informatics and Rights CNIL approval number 1171457, 24 May 2006, http://www.nadis.fr/), designed for the medical follow-up of HIV-infected patients, which also included their agreement to participate in retrospective studies. Figure 1 . Flow chart of the retrospective study.
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ARV plasma concentration determination
Blood samples were collected from the patients 12 6 2 or 24 6 4 h after the last ARV drug administration according to a twice-daily or once-daily ARV regimen, respectively, to assess minimal plasma concentrations (C 12 or C 24 ), except for NRTIs and efavirenz, for which C 12 was considered. For this last drug, usually taken once daily in the evening, its long elimination halflife (44-55 h) leads to minor plasma concentration variation over the day at steady state. On the contrary, the short half-lives of abacavir and lamivudine lead to a high proportion of trough concentrations below the limit of quantification (LOQ), and most patients have a concentration available 12 h after the last intake. Only one sample was considered for each patient, to maintain equal contributions of all the included patients in the analysis. ARV drug plasma concentrations were determined by LC with tandem MS (Acquity UPLC/TQD, Waters Corp., Milford, MA, USA) as described. 21 The LOQ was defined as 30 ng/mL for ritonavir, 20 ng/mL for efavirenz, nevirapine and lopinavir, and 5 ng/mL for atazanavir, darunavir, etravirine and raltegravir. Concentrations below the LOQ were set by convention as LOQ/2 for statistical analysis. ARV drug plasma concentrations were interpreted using the thresholds of antiviral efficacy routinely used in patient follow-up in Bichat hospital, from the US National Institutes of Health recommendations 9 for atazanavir, efavirenz and nevirapine (150, 1000 and 3000 ng/mL, respectively) or from clinical study, 22 -25 based on in vitro antiviral activity, for lopinavir, darunavir, etravirine and raltegravir (3000, 550, 200 and 50 ng/mL, respectively). NRTI C 12/24 values were interpreted in relation to usual values corresponding to the respective daily doses. Tolerance thresholds were considered for atazanavir (850 ng/mL), lopinavir (8000 ng/mL), efavirenz (4000 ng/mL), etravirine (950 ng/mL) and nevirapine (6000 ng/mL), for which a concentration-toxicity relationship was documented. 3 For tenofovir C 12 , a toxicity threshold was previously determined at 160 ng/mL. 26 No direct assessment of patient adherence to ART was available in the database; an indirect measure of patient adherence was therefore estimated as the number of ARV drug concentrations below the LOQ in each group.
Immuno-virological assessment
Plasma HIV-1 RNA was assessed by using the COBAS
.0 (Roche Molecular Systems, Branchburg, NJ, USA), with an LOQ of 20 copies/mL. Virological failure was considered as at least two consecutive plasma HIV RNA >50 copies/mL and otherwise virological success. Blood CD4þ T cells were counted by use of the FACSCanto II System (BD Biosciences).
Statistical analysis
Data are reported as median (IQR). Demographic and infection characteristics were compared between the obese and control groups using Fisher's exact test for categorical variables and a non-parametric Mann-Whitney test for continuous variables. Plasma concentrations for each ARV drug were compared using a Mann-Whitney test. Proportions of patients with concentrations below the efficacy threshold or above the toxicity threshold were compared for each drug, except ritonavir, abacavir, lamivudine and emtricitabine, using Fisher's exact test. Multivariate logistic regression analysis was performed to explore the association of suboptimal dosing (defined as at least one ARV drug plasma concentration below the efficacy threshold) and virological failure with obesity, on the day of concentration assessment and at 1 year of follow-up, adjusting for demographic and infection characteristics. Because of the small number of control patients included, matching was not considered for statistical analysis. Statistical analysis was performed using R software v3.2.2. (https://cran.rproject.org/).
Results
Patients
We identified 540 HIV-1-infected obese patients among the 4500 usually followed at Bichat-Claude Bernard Hospital; 291 of them matched the study eligibility criteria and were included ( Figure 1 and Table 1 ). We included 196 normal-weight matched patients. We were unable to include controls for each selected obese patient because of the demographic characteristics of patients followed at Bichat-Claude Bernard hospital and in particular the high prevalence of obesity in African women, added to the fact that concentration assays were not systematic for normal-weight patients, according to the French recommendations. 20 For obese patients, median (IQR) age and BMI were 44.7 years (38.5-51.8) and 32.8 kg/m 2 (31.1-35.4), respectively. Obese patients were more frequently women than men (59.8% versus 40.2%) and African ethnicity was the most represented (74.2%). Median (IQR) time from HIV infection diagnosis, time on ART and time on current ART on the day of concentration assessment was 8 years (6-12), 6 years (3-10) and 1.5 years (0.6-2.4), respectively. First-line therapy patients accounted for 21.3% of the obese patients. Virological success was observed in 88.3% of obese patients, and median (IQR) CD4þ T cell count was 510 cells/mm 3 (397-719). Demographic characteristics did not differ between obese and control patients, except for gender, with a greater proportion of obese women (59.8% versus 42.3%, P < 0.001). Median time from HIV infection diagnosis and time on ART were shorter for obese patients than controls (8 and 6 versus 10 and 8 years, P ¼ 0.03 and 0.05, respectively), yet median time on current ART was longer (1.5 versus 0.9 years, P < 0.001). The proportion of virological success was similar in the two groups, but CD4þ T cell count was higher for obese patients than controls (510 versus 444 cells/mm 3 , P < 0.001).
ARV drug plasma concentrations
To analyse the 12 ARVs, we assayed 881 plasma concentrations from obese patients and 585 from controls. For each drug, at least 80% of patients received treatment according to French national recommendations:
3,20 600 mg once daily for abacavir and efavirenz, 200 mg once daily for emtricitabine, 300 mg once daily for lamivudine and tenofovir disoproxil fumarate, 200 mg twice daily/ 400 mg once daily for etravirine, 200 mg twice daily for nevirapine, 400/100 mg twice daily for lopinavir combined with ritonavir, 300/100 mg once daily for atazanavir combined with ritonavir and 400 mg twice daily for raltegravir. For darunavir, the two dosing regimens combined with ritonavir, 800/100 mg once daily and 600/100 mg twice daily, were analysed separately because of the short half-life of darunavir. Ritonavir concentrations were compared by dosing regimen, 100 mg twice daily and 100 mg once daily.
For the NRTIs, median (IQR) tenofovir C 12 was lower by 23% for obese than for normal-weight patients [66 (48-84) versus 86 ng/ mL (54-117), P < 0.001] (Figure 2 ). No significant difference was found for abacavir, emtricitabine and lamivudine. Tenofovir concentration difference was also significant for patients receiving tritherapy with two NRTIs and one NNRTI (P ¼ 0.013), but not for patients treated with two NRTIs and one PI (P ¼ 0.11) (Figure 3 ). For the NNRTIs, median (IQR) plasma C 12 for efavirenz was lower, by Obesity and antiretroviral pharmacokinetics JAC 26%, for obese than control patients [1498 (1091-2292) versus 2034 ng/mL (1566-3181), P < 0.001] (Figure 2) , with no significant difference for nevirapine and etravirine. For the PIs, median plasma concentration for lopinavir was also lower, by 28%, for obese than control patients [4595 (3446-6136) versus 6420 ng/mL (5215-7677), P < 0.001], with no difference for atazanavir and darunavir (Figure 2 ). Ritonavir concentrations showed discrepancies comparable to those for lopinavir, with median trough concentrations of 79 (40-123) and 69 ng/mL (33-115) for obese patients and 256 (150-370) and 162 ng/mL (50-303) for controls when administered at 100 mg twice daily and 100 mg once daily, respectively (P < 0.001 and P < 0.001). Finally, median C 12 for raltegravir was 44% lower for obese than control patients [120 (62-256) versus 215 ng/mL (145-300)], but not significantly (P ¼ 0.082).
Obese patients showed plasma concentrations below the efficacy threshold depending on the ARV drug considered (Table 2) , with proportions of patients >15% for efavirenz, nevirapine, etravirine and raltegravir and up to 24.4% for lopinavir. This suboptimal dosing was not present in the control group, with only one patient (2.5%) showing C 24 <550 ng/mL with darunavir once daily. Proportions significantly differed between the two groups for efavirenz (P < 0.001) and lopinavir (P ¼ 0.002). Considering concentrations above the toxicity threshold, controls did not differ from obese patients for the five drugs considered (Table 2) .
We found no major compliance issue in either group; only four obese patients had undetectable concentrations for all ARV drugs, because of a probable lack of adherence.
Multivariate analysis
All the available demographic and infection characteristics were included in the multivariate logistic regression models, except for time under ART, which was largely correlated with time since HIV diagnosis.
The risk of at least one ARV drug concentration being below the efficacy threshold was strongly associated with obesity ( Madelain et al.
Figure 2. Trough plasma concentrations of etravirine (ETR), nevirapine (NVP), lopinavir (LPV) and darunavir once daily and twice daily (DRV QD and DRV BID), atazanavir (ATV) and raltegravir (RAL), and C 12 concentrations of efavirenz (EFV), abacavir (ABC), lamivudine (3TC), emtricitabine (FTC) and tenofovir (TFV) in obese (dark grey) and normal-weight patients (light grey). Number of patients (upper part of boxplot) and median concentration
drug plasma concentration assessment, we found no association with any of the variables included in the multivariate model (Table 4) .
One year of follow-up and drug switch
During the follow-up period, from the day of ARV drug concentration assessment to the end of the study period, 157 (54.0%) obese patients and 110 (56.1%) controls had at least one drug switch (Table 5) , with no difference between the groups in proportion of switches (P ¼ 0.71), time before switch (P ¼ 0.19), change in BMI (P ¼ 0.18) or virological failure at the time of the switch (P ¼ 0.45). However, reasons advocated by physicians for the switch differed between the groups (global v 2 test, P < 0.01), with therapeutic simplification the most frequent cause for obese patients and occurrence of adverse events for controls.
Discussion
Here, we report for the first time the pharmacokinetics of several ARV drugs in obese HIV-infected patients in the context of usual medical care. Considering ARV drugs of the NRTI, NNRTI, PI and integrase inhibitor classes, our study highlights significantly lower plasma concentrations in obese patients for tenofovir (À23%), efavirenz (À24%) and lopinavir (À28%) and a trend for raltegravir (À44%), for a significantly greater proportion of infected obese patients with potential inefficient drug exposure than infected normalweight patients (17.5% versus 0.5%). However, we found no deleterious impact of this suboptimal dosing on this virologically controlled population, even 1 year after drug concentration assessment.
Obesity is known to alter the pharmacokinetics of numerous drugs. In our study, obesity affected plasma concentrations of four ARVs: tenofovir, efavirenz, lopinavir and ritonavir. Although tenofovir is a hydrophilic molecule, its ester prodrug, tenofovir disoproxil, is far more lipophilic (logP octanol/water 1.25). Low body weight was previously reported to be associated with high tenofovir plasma concentrations in Caucasian women. 27 We report here a similar association between concentration and BMI in an obese population. Interestingly, this discrepancy seems to be reduced in patients receiving PIs. This observation may be related to the renal drug-drug interaction described with PIs, decreasing tenofovir clearance 28 and protecting obese patients from the concentration drop observed with other ARV drugs. Efavirenz is a lipophilic drug (logP octanol/water 4.6), with high binding to albumin (99.5%), 29 and demonstrates a high affinity for adipose tissue, with concentrations up to 100-fold higher than in plasma. 10 Underdosing was reported in patients with this drug. 30, 31 Therefore, the obesity impact was expected, and an explanation might be the sequestration of Obesity and antiretroviral pharmacokinetics JAC drug in adipose tissue, thereby lowering plasma concentration and making it unavailable to target compartments. These results were more unexpected for lopinavir and may have different physiological causes. Even if lopinavir largely binds to plasma proteins and has high logP octanol/water (5.9), it undergoes fast metabolism mediated by cytochrome P450 3A isoenzymes, 32 resulting in a short half-life of 5-6 h. Drugs of the same class were not found to accumulate in fat tissue, 10 yet a body weight effect was found in pregnant women 33 and children 34 for both distribution and clearance. Interestingly, ritonavir, closely related to lopinavir structurally, presented the same concentration pattern between our obese and normal-weight patients. Finally, we observed a trend for raltegravir in terms of reduced concentration in obese patients, associated with high variability, but the small number of patients receiving this drug (n < 30) does not allow robust conclusions. Raltegravir does not have a lipophilic profile (logP octanol/water 0.4), but has reduced solubility in acid aqueous solution. Thus, its gastrointestinal absorption largely depends on gastric pH. Gastrooesophageal reflux disease, affecting $50% of obese patients, 35 may reduce raltegravir's bioavailability and further increase the high inter-individual variability in plasma concentrations.
The multivariate analysis found a strong effect of obesity on the risk of having a concentration below threshold, reflecting the results of the univariate analysis. An explanation of the moderate effect of the time from HIV diagnosis may be that older patients receive lopinavir, for which concentrations were more often under threshold than for the more recent PIs darunavir and atazanavir. Unfortunately, we were not able to include all the potential confounding factors that may have impacted ARV drug concentrations in this analysis. Genetic polymorphism of metabolic enzymes would have been of interest, for instance CYP2B6, for which SNPs have been described to affect efavirenz concentrations. 36 Close adherence measurement, such as self-reporting or Medication Event Monitoring System (MEMS), would also improve this work, but these methods are not easily applied in routine practice because of cost effectiveness concerns. Even if a concentration assay might not be the most sensitive assessment, having only four patients with all concentrations below the LOQ made it unlikely that there was a major compliance issue in this study.
The high frequency of ARV drug concentrations below the efficacy threshold in obese patients was not associated with loss of virological control, either in the global cohort or in the subgroups receiving efavirenz or lopinavir (data not shown). This result should be interpreted cautiously considering that ARV drug cut-offs were defined for induction treatment, aiming to quickly decrease viral load in patients initiating treatment. The patients included in this Madelain et al. study were in the maintenance stage (median of 7 years with current treatment) and may not have required such stringent concentration levels to control viral replication.
The two patient groups presented similar rates of virological failure on the day of drug assessment, after 1 year of follow-up, and at drug switch for those who changed treatment. Virological control is multifactorial, depending notably on viral resistance and immunological background and considering treatment, observance and other ARV drugs administered. Immunological response was better for obese than normal-weight patients, as previously reported. 1, 11 Overall, our results largely agree with those recently reported from a large cohort of patients receiving efavirenz, 37 showing that obesity does not affect virological and immunological response, despite potential reduced ARV drug exposure.
Conclusions
The increasing rate of obesity among HIV-infected patients requires adapted medical care. We showed that obesity affects the pharmacokinetics of three previously frequently prescribed ARV drugs, tenofovir, efavirenz and lopinavir; it lowers the plasma concentrations of the drugs and is likely to affect the pharmacokinetics of other ARV drugs. In addition, the observed high variability in concentrations implies that some patients may be overdosed. An extension of this study to new ARV drugs recently available, such as dolutegravir, elvitegravir or rilpivirine, would be of interest. We did not demonstrate an impact of these concentrations on virological or immunological control, arguing that obese patients with maintenance ART would not suffer from this suboptimal exposure. However, these results may encourage therapeutic drug monitoring in this population at induction, when plasma viral load is high, or when resistance mutations are present and higher therapeutic concentrations are needed.
